Potential New Drugs from Underwater Forests Discovered
Potential New Drugs from Underwater Forests Discovered
Natural products have been essential against bacterial infections and other diseases such as cancer. Disturbingly, drug resistant infections are rapidly increasing and are attributed to the widespread use of antibiotics. Around half of the microbe-derived drug candidates are from Actinobacteria. There is an urgent need to find novel molecules to treat drug resistant infections and disease. Recently, several novel drugs have originated from marine Actinobacteria. Laminaria ochroleuca form kelp forests that are one of the most productive and dynamic ecosystems that may contain the answer to defeating drug-resistant superbugs.
In a recent report, L. ochroleuca was harvested and processed and was found to contain a rich source of bacteria with antimicrobial and anticancer activity. Researchers isolated 90 Actinobacterial strains that were screened for antimicrobial and anticancer activity. Forty-five isolates inhibited the growth of Candida albicans and/or Staphylococcus aureus. Seven extracts affected the viability of cancer cells with 28 extracts affecting the viability of at least one human cancer cell line. This study highlights the invaluable source of marine Actinobacteria with potential antimicrobial and anticancer activities. Further isolation and testing on other types of algae to uncover valuable sources is needed to discover new bioactive compounds.
Enzo Life Sciences provides a wide variety of products for your Drug Discovery and Bioprocess research needs. From target discovery and validation to formulation and manufacturing, Enzo offers a line of products and services that can accelerate your drug discovery program. Choose from an extensive range of antibodies, proteins, compound libraries for primary and secondary screening, Immunoassays and Assay Kits for reliable biomarker detection, and cytotoxicity assays for in vitro drug safety assessment. Our aim is to deliver innovative tools that make drug development more efficient, more cost-effective and more successful.
Multiplex assay that distinguishes between healthy, early apoptotic, late apoptotic and necrotic cells, compatible with GFP and other fluorescent probes (blue or cyan)
Flow Cytometry, Fluorescence microscopy, Fluorescent detection | Print as PDF
Sensitive (30 ng/ml) ELISA for the quantitative determination of host cell protein contamination in bulk products expressed in E. coli expression systems.
Sensitive (10 ng/ml) ELISA for the quantitative determination of host cell protein contamination in bulk products expressed in Chinese Hamster Ovary (CHO) expression systems.